Levetiracetam Sandoz

Levetiracetam, the active ingredient in Levetiracetam Sandoz, is an anticonvulsant presented as an intravenous solution for intravenous use. It treats a range of seizure types and is employed in patients with epilepsy, including those experiencing status epilepticus.

GNH USA supplies Levetiracetam Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Levetiracetam is an antiepileptic agent used to manage seizure disorders.

- Partial‑onset seizures: reduces seizure frequency as adjunctive therapy. - Generalized tonic‑clonic seizures: provides adjunctive seizure control. - Myoclonic seizures: helps control myoclonic episodes when added to existing therapy. - Status epilepticus: administered intravenously for rapid seizure termination.

Levetiracetam may cause a range of adverse reactions, most of which are mild to moderate in severity.

Common Side Effects: - Dizziness: transient feeling of light‑headedness. - Somnolence: increased sleepiness or fatigue. - Headache: mild to moderate cranial pain. - Irritability: mood changes or agitation. - Nausea: occasional gastrointestinal upset. - Fatigue: general lack of energy.

Serious or Rare Side Effects: - Severe allergic reaction: rash, swelling, or anaphylaxis. - Stevens‑Johnson syndrome: rare skin disorder with blistering. - Suicidal ideation: thoughts of self‑harm. - Severe depression: marked mood disturbances. - Blood dyscrasias: abnormal blood counts. - Respiratory depression: difficulty breathing, especially with concomitant CNS depressants.

Before initiating therapy, clinicians should assess patient‑specific factors and monitor for potential complications.

- Renal impairment: adjust dose based on creatinine clearance. - Psychiatric symptoms: monitor for mood changes, depression, or suicidal thoughts. - Hypersensitivity: discontinue if rash or anaphylaxis occurs. - Pregnancy: risk category unknown; weigh benefits against potential risks. - Discontinuation: avoid abrupt cessation to prevent seizure worsening. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Levetiracetam has a relatively low interaction profile, but certain co‑medications may require attention.

Major Interactions (Avoid): - Concomitant CNS depressants: may increase sedation or respiratory depression. - Strong enzyme inducers (e.g., carbamazepine, phenytoin, phenobarbital): can markedly reduce levetiracetam plasma levels.

Moderate Interactions (Monitor Closely): - Other antiepileptic drugs: may require dose adjustments for optimal seizure control. - Antidepressants or antipsychotics: monitor for additive psychiatric effects. - Renal‑clearing drugs: assess renal function to avoid accumulation.